Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 6/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25952640 | 0.90 | DDB1 (0.36) | DDB1CRBNKIF11TP53 | |
| SCHEMBL25905898 | 0.88 | CRBN (0.49) | DDB1CRBN | |
| SCHEMBL25952605 | 0.84 | DDB1 (0.47) | DDB1CRBNALDH1A1KIF11 | |
| SCHEMBL27048776 | 0.82 | DDB1 (0.36) | DDB1CRBNKIF11TP53 | |
| SCHEMBL25952629 | 0.81 | DDB1 (0.34) | DDB1CRBNALDH1A1KIF11HPGD | |
| SCHEMBL25952610 | 0.80 | DDB1 (0.35) | DDB1CRBNALDH1A1KIF11 | |
| SCHEMBL25952602 | 0.80 | DDB1 (0.46) | DDB1CRBNALDH1A1HPGDMAPT | |
| SCHEMBL25952627 | 0.79 | MGAT2 (0.35) | DDB1CRBNKIF11 | |
| SCHEMBL25666681 | 0.77 | CRBN (0.47) | DDB1CRBNMAPT | |
| SCHEMBL25960907 | 0.77 | CRBN (0.49) | DDB1CRBNTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | DDB1 438/4885CRBN 144/4885ALDH1A1 3281/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | DDB1 438/4885CRBN 144/4885ALDH1A1 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.